Identified compounds demonstrate protein kinase inhibitory activity and inhibition of dependent cell signaling pathways, such as NOD2 cell signaling. More specifically, the compounds are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin-like kinase 2 (ALK2). Compounds that are either dual RIPK2/ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 could provide therapeutic benefit.
鉴定出的化合物具有蛋白激酶抑制活性,并能抑制依赖性细胞信号传导途径,如 NOD2 细胞信号传导。更具体地说,这些化合物具有抑制受体互作激酶 2 (RIPK2) 和/或类激酶 2 (ALK2) 的作用。RIPK2/ALK2双重
抑制剂或优先抑制RIPK2或ALK2的化合物可带来治疗效果。